[1]
Abdullah, B.; Alias, A.; Hassan, S. Challenges in the management of nasopharyngeal carcinoma: a review. Malays. J. Med. Sci., 2009, 16(4), 50-54.
[2]
Zhang, L.; Chen, Q.Y.; Liu, H.; Tang, L.Q.; Mai, H.Q. Emerging treatment options for nasopharyngeal carcinoma. Drug Des. Devel. Ther., 2013, 7, 37-52.
[3]
P.B. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res., 1974, 34(5), 1189-1191.
[4]
Hui, E.P.; Leung, S.F.; Au, J.S.; Zee, B.; Tung, S.; Chua, D.; Sze, W.M.; Law, C.K.; Leung, T.W.; Chan, A.T. Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer, 2004, 101(2), 300-306.
[5]
Su, S.F.; Han, F.; Zhao, C.; Huang, Y.; Chen, C.Y.; Xiao, W.W.; Li, J.X.; Lu, T.X. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Chin. J. Cancer, 2011, 30(8), 565-573.
[6]
Chang, J.T.; See, L.C.; Liao, C.T.; Ng, S.H.; Wang, C.H.; Chen, I.H.; Tsang, N.M.; Tseng, C.K.; Tang, S.G.; Hong, J.H. Locally recurrent nasopharyngeal carcinoma. Radiother. Oncol., 2000, 54(2), 135-142.
[7]
Lo, K.W.; Huang, D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol., 2002, 12(6), 451-462.
[8]
Tao, Q.; Chan, A.T. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med., 2007, 9(12), 1-24.
[9]
Chou, J.; Lin, Y.C.; Kim, J.; You, L.; Xu, Z.; He, B.; Jablons, D.M. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck, 2008, 30(7), 946-963.
[10]
Li, L.L.; Shu, X.S.; Wang, Z.H.; Cao, Y.; Tao, Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin. J. Cancer, 2011, 30(4), 231-239.
[11]
Lo, K.W.; To, K.F.; Huang, D.P. Focus on nasopharyngeal carcinoma. Cancer Cell, 2004, 5(5), 423-428.
[12]
Abdel Khalek Abdel Razek, A.; King, A. MRI and CT of nasopharyngeal carcinoma. AJR Am. J. Roentgenol., 2012, 198(1), 11-18.
[13]
Di Leva, G.; Garofalo, M.; Croce, C.M. MicroRNAs in cancer. Annu. Rev. Pathol., 2014, 9, 287-314.
[14]
Iorio, M.V.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Menard, S.; Palazzo, J.P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G.A.; Querzoli, P.; Negrini, M.; Croce, C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 2005, 65(16), 7065-7070.
[15]
Hiyoshi, Y.; Kamohara, H.; Karashima, R.; Sato, N.; Imamura, Y.; Nagai, Y.; Yoshida, N.; Toyama, E.; Hayashi, N.; Watanabe, M.; Baba, H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin. Cancer Res., 2009, 15(6), 1915-1922.
[16]
Ma, L.; Teruya-Feldstein, J.; Weinberg, R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 2007, 449(7163), 682-688.
[17]
Ma, J.; Dong, C.; Ji, C. MicroRNA and drug resistance. Cancer Gene Ther., 2010, 17(8), 523-531.
[18]
Nicoloso, M.S.; Spizzo, R.; Shimizu, M.; Rossi, S.; Calin, G.A. MicroRNAs--the micro steering wheel of tumour metastases. Nat. Rev. Cancer, 2009, 9(4), 293-302.
[19]
Hurst, D.R.; Edmonds, M.D.; Welch, D.R. Metastamir: The Field of Metastasis-Regulatory microRNA Is Spreading. Cancer Res., 2009, 69(19), 7495-7498.
[20]
Lu, J.A.; He, M.L.; Wang, L.; Chen, Y.; Liu, X.O.; Dong, Q.; Chen, Y.C.; Peng, Y.; Yao, K.T.; Kung, H.F.; Li, X.P. MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2. Cancer Res., 2011, 71(1), 225-233.
[21]
Deng, M.; Tang, H.L.; Zhou, Y.H.; Zhou, M.; Xiong, W.; Zheng, Y.; Ye, Q.R.; Zeng, X.; Liao, Q.J.; Guo, X.F.; Li, X.L.; Ma, J.; Li, G.Y. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J. Cell Sci., 2011, 124(17), 2997-3005.
[22]
Zhang, L.Y.; Lee, V.H.F.; Wong, A.M.G.; Kwong, D.L.W.; Zhu, Y.H.; Dong, S.S.; Kong, K.L.; Chen, J.; Tsao, S.W.; Guan, X.Y.; Fu, L. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis, 2013, 34(2), 454-463.
[23]
Luo, Z.; Dai, Y.; Zhang, L.; Jiang, C.; Li, Z.; Yang, J.; McCarthy, J.B.; She, X.; Zhang, W.; Ma, J.; Xiong, W.; Wu, M.; Lu, J.; Li, X.; Li, X.; Xiang, J.; Li, G. miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis, 2013, 34(2), 415-425.
[24]
Okumura, H.; Kita, Y.; Yokomakura, N.; Uchikado, Y.; Setoyama, T.; Sakurai, H.; Omoto, I.; Matsumoto, M.; Owaki, T.; Ishigami, S.; Natsugoe, S. Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res., 2010, 30(12), 5175-5179.
[25]
Wang, Z.H.; Trope, C.G.; Suo, Z.H.; Troen, G.; Yang, G.R.; Nesland, J.M.; Holm, R. The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer, 2008, 8, 308.
[26]
Chen, L.W.; Yang, B. 14-3-3 Sigma is a useful immunohistochemical marker for diagnosing ovarian granulosa cell tumors and steroid cell tumors. Int. J. Gynecol. Pathol., 2013, 32(2), 156-162.
[27]
Ravi, D.; Chen, Y.; Karia, B.; Brown, A.; Gu, T.T.; Li, J.; Carey, M.S.; Hennessy, B.T.; Bishop, A.J. 14-3-3 sigma expression effects G2/M response to oxygen and correlates with ovarian cancer metastasis. PLoS One, 2011, 6(1), e15864.
[28]
Huang, W-G.; Cheng, A.L.; Chen, Z.C.; Peng, F. Targeted proteomic analysis of 14-3-3σ in nasopharyngeal carcinom. Int. J. Biochem. Cell Biol., 2010, 42(1), 137-147.
[29]
Cheng, A.L.; Huang, W.G.; Chen, Z.C.; Peng, F.; Zhang, P.F.; Li, M.Y.; Li, F.; Li, J.L.; Li, C.; Yi, H.; Yi, B.; Xiao, Z.Q. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin. Cancer Res., 2008, 14(2), 435-445.
[30]
Yi, B.; Tan, S.X.; Tang, C.E.; Huang, W.G.; Cheng, A.L.; Li, C.; Zhang, P.F.; Li, M.Y.; Li, J.L.; Yi, H.; Peng, F.; Chen, Z.C.; Xiao, Z.Q. Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J. Cell. Biochem., 2009, 106(5), 858-866.
[31]
Hermeking, H.; Lengauer, C.; Polyak, K.; He, T.C.; Zhang, L. Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell, 1997, 1, 3-11.
[32]
Yang, H.Y.; Wen, Y.Y.; Lin, Y.I.; Pham, L.; Su, C.H.; Yang, H.; Chen, J.; Lee, M.H. Roles for negative cell regulator 14-3-3sigma in control of MDM2 activities. Oncogene, 2007, 26(52), 7355-7362.
[33]
Mackintosh, C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem. J., 2004, 381(Pt 2), 329-342.
[34]
Morrison, D.K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol., 2009, 19(1), 16-23.
[35]
Moreira, J.M.; Ohlsson, G.; Rank, F.E.; Celis, J.E. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol. Cell. Proteomics, 2005, 4(4), 555-569.
[36]
Yang, H.; Zhao, R.; Lee, M.H. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol. Cancer Ther., 2006, 5(2), 253-260.
[37]
Dweep, H.; Sticht, C.; Pandey, P.; Gretz, N. miRWalk--database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J. Biomed. Inform., 2011, 44(5), 839-847.
[38]
Kumar, A.; Wong, A.K.L.; Lizard, M.L.; Moore, R.J.; Lefevre, C. miRNA_Targets: A database for miRNA target predictions in coding and non-coding regions of mRNAs. Genomics, 2012, 100(6), 352-356.
[39]
Chiang, H.R.; Schoenfeld, L.W.; Ruby, J.G.; Auyeung, V.C.; Spies, N.; Baek, D.; Johnston, W.K.; Russ, C.; Luo, S.J.; Babiarz, J.E.; Blelloch, R.; Schroth, G.P.; Nusbaum, C.; Bartel, D.P. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev., 2010, 24(10), 992-1009.
[40]
Betel, D.; Koppal, A.; Agius, P.; Sander, C.; Leslie, C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol., 2010, 11(8)
[41]
Cammarata, G.; Augugliaro, L.; Salemi, D.; Agueli, C.; La Rosa, M.; Dagnino, L.; Civiletto, G.; Messana, F.; Marfia, A.; Bica, M.G.; Cascio, L.; Floridia, P.M.; Mineo, A.M.; Russo, M.; Fabbiano, F.; Santoro, A. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am. J. Hematol., 2010, 85(5), 331-339.
[42]
Han, Z.B.; Zhong, L.; Teng, M.J.; Fan, J.W.; Tang, H.M.; Wu, J.Y.; Chen, H.Y.; Wang, Z.W.; Qiu, G.Q.; Peng, Z.H. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol. Oncol., 2012, 6(4), 445-457.
85
8
4
1